Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778895 | 0.98 | CA1 (0.69) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL13016336 | 0.95 | CA1 (0.65) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL3418284 | 0.93 | CA1 (0.83) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL30787956 | 0.93 | CA1 (0.83) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL12025738 | 0.91 | CA1 (0.80) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL26182867 | 0.89 | MGLL (0.59) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL1093598 | 0.87 | CA1 (0.62) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL28394087 | 0.86 | CA1 (0.61) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL20489328 | 0.86 | CA1 (0.53) | CA1CA2ESR1ESR2PLG | |
| SCHEMBL9612410 | 0.85 | CA1 (0.70) | CA1CA2PLGF12F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8568903-B2 | Phenanthrene derivative, and material for organic EL element | IDEMITSU KOSAN CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8568903-B2 | Phenanthrene derivative, and material for organic EL element | IDEMITSU KOSAN CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8568903-B2 | Phenanthrene derivative, and material for organic EL element | IDEMITSU KOSAN CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20100327230-A1 | PHENANTHRENE DERIVATIVE, AND MATERIAL FOR ORGANIC EL ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100327230-A1 | PHENANTHRENE DERIVATIVE, AND MATERIAL FOR ORGANIC EL ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100327230-A1 | PHENANTHRENE DERIVATIVE, AND MATERIAL FOR ORGANIC EL ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100327230-A1 | PHENANTHRENE DERIVATIVE, AND MATERIAL FOR ORGANIC EL ELEMENT | LEF1, AR, NR0B1 | CA1 2652/4885CA2 2860/4885ESR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.